Veradermics: VDPHL01 Looks Promising Enough On Paper
MANE's main drug candidate is VDPHL01. This asset already has encouraging male and female data for hair loss. However, VDPHL01 still needs pivotal data to make it ready for a potential FDA submission. If approved, VDPHL01 would compete as a cash-pay prescription treatment for pattern hair loss, which would let MANE tap into a sizeable TAM.
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript
Veradermics, Incorporated (MANE) Discusses Positive Female Results From Phase II Study of VDPHL01 for Pattern Hair Loss Transcript
Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women
Veradermics NYSE: MANE said results from the female arms of Study 207, a phase II open-label trial of VDPHL01 for mild to moderate pattern hair loss, showed what company executives described as a strong proof-of-concept signal for the oral treatment.
Veradermics: Positive VDPHL01 Data Strengthens Late-Stage Pipeline Thesis
Veradermics delivered robust Phase 2/3 data for VDPHL01, showing 30–33 hairs/cm² regrowth vs. 7/cm² placebo and placebo-like safety. MANE's late-stage, oral, extended-release minoxidil targets a large, underserved cash-pay hair loss market, with rapid onset and high patient satisfaction. The current $3.7B market cap reflects high expectations for VDPHL01's regulatory approval and commercialization as a first-in-class oral therapy.
Veradermics, Incorporated (MANE) Discusses Positive Topline Results from Phase 2/3 Study of VDPHL01 for Mild-to-Moderate Pattern Hair Loss Transcript
Veradermics, Incorporated (MANE) Discusses Positive Topline Results from Phase 2/3 Study of VDPHL01 for Mild-to-Moderate Pattern Hair Loss Transcript
Veradermics eyes FDA first as Jefferies initiates at 'buy'; sees 75% upside on oral hair loss pill
Jefferies is initiating coverage of Veradermics with a 'buy' rating, betting that a smarter formulation of an old drug could unlock a $2 billion market Minoxidil has been around for decades. Millions of people rub it into their scalps every day, and a growing number take low-dose oral versions off-label.
